Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTHE: Avidin-biotin-DOTA-90Y in Nonpalpable Breast Cancer
NCT06390241Phase 1Terminated
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Jun 2024
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of avidin + yttrium-90-DOTA-biotin in breast cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Primary endpoints: Safety of avidin-biotin-Dota-90Y and Anti-tumor activity of avidin-biotin-Dota-90Y. Started Jun 2024; status: terminated.
02
Drugs
avidin + yttrium-90-DOTA-biotin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06390241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390241.